Board of Directors

COMMITTED TO CHANGING THE FACE OF CANCER TREATMENT

The BioCanRx Board of Directors is responsible for ensuring financial accountability, scientific excellence, knowledge exchange and operational efficiency. The board approves policies and procedures consistent with the goals and mission of the network. It also determines the mandate, membership, authority and makeup of committees.

The Board provides leadership and direction to BioCanRx so that it remains on target with respect to its strategic plan and commitment to the NCE mandate.

MEMBERS OF THE BOARD:


Russell Williams Chair, Board of Directors	Dr. John Bell Scientific Director, BioCanRx Senior Scientist, The Ottawa Hospital Professor, uOttawa	Dr. Josée Brisebois Executive Consultant, Biopharma & Health Sciences Sectors	Dr. David Poon Co-Founder, Head of Business DCx Biotherapeutics

Doreen Hume Partner, Audit & Assurance, Deloitte Canada	Dr. John Stagg Associate Professor, Faculty of Pharmacy at the University of Montreal Lab Head at the CHUM Hospital Research Centre	Antonia Palmer Co-Founder at Ac2orn: Advocacy for Canadian Childhood Oncology Research Network	Brigette Kocijancic ABC, PROSCI Certified Global Communications & Change Management Consultant

Mỹ Dang Director of Regulatory Affairs, Innomar Strategies	Sebastien Beauchamp LL.M, MBA, ICD.D Vice-President, Government Relations and Corporate Development, Dynacare	Dr. Jumai Abioye Founder and CEO PanAccess Innovations Inc.